Readers hitting this cluster for the first time can end up with the impression that 5-MeO-DMT, mebufotenin, and GH001 are just three interchangeable names for the same thing. That is the wrong mental model.
The clean plain-English version is simpler. At the compound-name layer, you will run into 5-MeO-DMT and mebufotenin. GH001 belongs to a different layer: it is the name of GH Research’s program/formulation under study for treatment-resistant depression. If you remember only one thing, remember that GH001 is not just another loose synonym in the stack.
What the paper says
The peer-reviewed paper is the cleanest starting point because it makes the program-to-compound relationship explicit. The PubMed record for the randomized JAMA Psychiatry trial describes GH001 as a synthetic formulation of inhaled mebufotenin. That is more precise than saying every label in the cluster is the same thing, and it is why the paper is the best anchor when shorthand starts to drift.
What ClinicalTrials.gov says
The registry record is filed as a trial of GH001 in patients with treatment-resistant depression. That is useful because it keeps the reader oriented around the clinical program, not just the chemistry label. But it is also one reason people get confused: registry language often stays focused on the study name, condition, and administration details rather than unpacking every naming layer the way an explainer has to.
What the company materials say
GH Research’s investor-relations materials center the program name GH001, especially in the Jan. 5 release on the FDA clinical-hold lift. But the Mar. 25 publication release is also useful because it explicitly pairs the compound and asset layers in one line: mebufotenin (GH001). That pairing helps readers connect the evidence package, but it can also make the stack look flatter than it really is.
Why media shorthand drifts
Once the paper, the registry, and company materials are each emphasizing a slightly different layer, shorthand in coverage starts to compress the stack. A reader sees a compound label, a program label, and a headline claim about trial results, and the names blur together. That does not necessarily make the underlying reporting false. It does make it easier for coverage to imply that a company asset name, a formulation description, and a compound label are all interchangeable when they are not.
The clean way to read this cluster
The safest read is to keep three questions separate. First, what is the compound-name layer people are talking about? Second, what is the actual clinical program name? Third, which source is carrying which claim? In this case, the paper gives the cleanest compound-to-program phrasing, the registry keeps the study framed as GH001, and the company materials package the same evidence in investor-facing language.
That is why the useful summary is not “all three names mean the same thing.” The useful summary is narrower and better: this evidence package sits around GH Research’s GH001 program, the paper explicitly describes that program as a synthetic formulation of inhaled mebufotenin, and readers should be careful whenever shorthand coverage starts collapsing every label in the cluster into one vague term.